The CINP 2021 Organizing Committee is continuing to closely monitor developments surrounding the ongoing COVID-19 pandemic and is currently evaluating the option of adding a virtual component to the Congress in addition to (or possibly in lieu of) the in-person congress.
This will allow symposia presenters to present remotely, and participants to attend virtually in case there are still travel restrictions or concerns at the time of the Congress. The Program Committee therefore encourages submissions for virtual symposia, with the flexibility of switching between in-person presentation and virtual presentation at a later date as circumstances evolve. Submitters are NOT required to commit to traveling to Montreal in November.
Symposia of 90 min duration integrate the latest advances in basic, clinical and translational neuropsychopharmacology, biological psychiatry, drug development public policy issues relevant to mental health, mental illness and treatment across the lifespan.
Four Speakers including the Chairperson should represent at least three different countries and four different institutions. It is recommended that at least two speakers should be CINP members. Symposia proposals that include female faculty and investigators who obtained their last degree in the last 10 years are greatly encouraged.
The individual who submits the symposium proposal via submission process below must be the Chairperson of their proposed session.
Submitters can apply for no more than two symposia and speakers can agree to participate in no more than two proposals.
CINP 2021 Symposia will be reviewed and selected on a highly competitive basis by the International Scientific Programme Committee in March 2021. Notifications will be sent to all symposia submitters in April 2021.
Speakers in successful symposia will receive the following entitlements:
|Symposia Submission Extended Deadline||Now Closed|
|Notification of Submission Acceptance||31 May 2021|
|Deadline for Change of Title/Authorship||15 July 2021|
Abstract submissions must be structured with the following:
License of copyright and consent to publication
All submitted proposals will be reviewed by the International Scientific Programme Committee and submitters will be informed whether successful or otherwise by end of April 12, 2021.
Each proposal will be judged on objective evidence on the following criteria:
The CINP International Scientific Programme Committee welcomes the proposal of symposia that link the latest, and ground-breaking, preclinical developments with the clinical research on a given topic. Through the free and open exchange of ideas, CINP supports a strong focus on new approaches to the development and assessment of CNS pharmaceuticals by researchers working in both academia and industry.
Please find below the list of topics.
The 33rd CINP World Congress of Neuropsychopharmacology will be taking place 1-4 November 2021 in Montreal, Canada.
Keep up to date with Congress News & Alerts